Mixed 2Q For ResMed
ResMed Inc. (NYSE:RMD) reported EPS of 42 cents in the second quarter of fiscal 2012, beating the Zacks Consensus Estimate of 38 cents and also the year-ago EPS by 14%. Revenues increased 9% year over year (flat at constant exchange rates or CER) to $332.7 million but missed the Zacks Consensus Estimate of $340 million. [...]
ResMed Inc. (NYSE:RMD) reported EPS of 42 cents in the second quarter of fiscal 2012, beating the Zacks Consensus Estimate of 38 cents and also the year-ago EPS by 14%. Revenues increased 9% year over year (flat at constant exchange rates or CER) to $332.7 million but missed the Zacks Consensus Estimate of $340 million. Following the earnings release, shares of ResMed surged 10.47% on Friday.
Based on a favorable product mix and vastly under-penetrated and growing sleep-disorder breathing market, … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards